6月18日，据CDE官网消息，康诺亚生物医药科技（成都）有限公司联合申请药品“CM512注射液”，获得临床试验默示许可，受理号CXSL2500275。
公示信息显示，药品“CM512注射液”适应症：支气管扩张。
康诺亚生物医药科技（成都）有限公司，成立于2016年，位于成都市，是一家以从事研究和试验发展为主的企业。企业注册资本29020.6858万美元，实缴资本17812.4635万美元。
通过天眼查大数据分析，康诺亚生物医药科技（成都）有限公司共对外投资了6家企业，参与招投标项目2次，知识产权方面有商标信息100条，专利信息27条，此外企业还拥有行政许可19个。
主要股东信息显示，康诺亚生物医药科技（成都）有限公司由一桥香港控股有限公司持股99.9573%、WEALTH VENTURE ENTERPRISES（HONG KONG）LIMITED持股0.0427%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.